- Home
- Aid by Sector
- Health
- Basic health
- Infectious disease control
Aid by Sector
UK Vaccine Network (UKVN) - Innovate UK - Vaccines for Epidemic Diseases: Readiness for clinical development and regulatory submission competition
UK - Department of Health and Social Care (DHSC)
This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s UK Vaccine Network (UKVN) which supports the development of vaccines and vaccine technology for infectious diseases with the potential to cause an epidemic in low- and middle-income countries (LMICs), focusing on areas of market failure. UKVN has identified a range of human diseases with epidemic potential in LMICs for which the development of vaccines is a priority. UKVN collaborated with Innovate UK to run a Small Business Research Initiative (SBRI) competition to invest in vaccines and vaccine technologies to address the priority disease families identified by UKVN (including Disease X - a pandemic pathogen that has not yet been characterised). Proposals could address any part of the pre-clinical, non-clinical, manufacturing, or clinical pathway, within a one-year time frame, making technology ready to be progressed further along the developmental pathway. The projects built on work from previous Innovate competitions, including: Innovate Clinical Vaccine Development Competition 2018/2021, Innovate Pre-clinical Vaccine Development Competition 2017/2021 and the Innovate Vaccine Development Competition to develop research across vaccine development. This project was not put out to an open, competitive tender process because, as a non-departmental public body of the UK government, Innovate UK is uniquely positioned to manage research calls.
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Vaccine Innovation with the Bacterial Vaccinology Network (BactiVac)
UK - Department of Health and Social Care (DHSC)
This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF). GAMRIF funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. This project is delivered in partnership with the Bacterial Vaccinology Network (BactiVac) to support the development of vaccines for antimicrobial resistance (AMR) in humans and animals. BactiVac is one of five networks that are supported by the Global Challenges Research Fund (GCRF) Networks in Vaccines Research and Development which is co-funded by the UK Medical Research Council (MRC) and the UK Biotechnology and Biological Sciences Research Council (BBSRC). The primary aim of this investment is to accelerate the development of vaccines against bacterial infections, so that antimicrobial use in humans and animals is reduced in LMICs. This investment also supports new, diverse research projects to gain preliminary data and encourage new research partnerships, and allow these collaborations to build a track record, which will allow them to obtain further funding. It is expected that some of these projects will not yield expected research results, yet the dissemination of both positive and negative research outcomes is valuable and expected. Funded projects will undertake early-stage research and development with catalyst pump-priming funding around the world to help drive the development and uptake of vaccines for AMR for the benefit of people in LMICs.
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Accelerating Antibacterial Innovation with Combating Antibiotic Resistant Bacteria Accelerator (CARB-X)
UK - Department of Health and Social Care (DHSC)
This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) which funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. This project is delivered in partnership with Boston University’s Combating Antibiotic Resistant Bacteria Accelerator (CARB-X), a non-profit, multi-donor international partnership that supports innovative early product research and development focused on the most dangerous drug-resistant bacteria. This partnership will invest in high-value, innovative research to accelerate the development of products to reduce the harm to human health, welfare and economic growth from drug-resistant infections, up to and including Phase I. The programme will focus on prevention (including vaccines) and alternatives to antibiotics for humans as primarily and directly relevant to people in LMICs.
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - InnoVet AMR: Innovative Veterinary Solutions for Antimicrobial Resistance (AMR) with the International Development Research Centre (IDRC)
UK - Department of Health and Social Care (DHSC)
This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) which funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. This project is delivered in partnership with the International Development Research Centre (IDRC) and aims to reduce the emerging risk that antimicrobial resistance (AMR) in animals poses to global health and food security. InnoVet-AMR will fund research to develop new animal vaccines and other innovations to fight AMR in livestock (swine and poultry) and aquaculture production, particularly in LMICs. Through InnoVet-AMR, DHSC and IDRC aim to achieve two main objectives: (1) Support research that will identify innovative veterinary solutions, including vaccines and alternative solutions, to reduce the use of antimicrobials in livestock and aquaculture operations in LMICs; and (2) Build effective partnerships to better coordinate discovery, development and sustainable delivery of affordable innovative veterinary solutions to reduce the use of antimicrobials in livestock and aquaculture operations in LMICs. As part of the InnoVet-AMR programme, GAMRIF has also allocated additional funding to a partnership with the International Centre for Antimicrobial Resistance Solutions (ICARS). This complimentary research activity will support scoping and research projects focused on climate change, gender and equity in AMR mitigation.
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Innovation in Antimicrobial Resistance (AMR) Diagnostic Tools with the Foundation for Innovative New Diagnostics (FIND)
UK - Department of Health and Social Care (DHSC)
This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) which funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. The project is delivered in partnership with the Foundation for Innovative New Diagnostics (FIND), a global non-profit product development partnership that aims to develop, evaluate and deliver high-quality affordable diagnostic tests for poverty-related diseases. Funding through GAMRIF will support FIND’s work to enhance the impact of diagnostic tools for AMR, improving AMR surveillance and antibiotic stewardship. This work has two areas of focus: (1) To develop technological methods to connect data from patient testing and health provider consultations to larger data systems, such as national and international AMR surveillance programmes. This will lead to improved antibiotic use and AMR surveillance through increased access to data; and (2) To develop new diagnostic technologies for drug-resistant gonorrhoea, which will enable improved diagnosis and therefore use of new antibiotics.
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - New Antibiotic Treatments with the Global Antibiotic Research and Development Partnership (GARDP) - Phase III
UK - Department of Health and Social Care (DHSC)
This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) which funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. The project is delivered in partnership with the Global Antibiotic Research and Development Partnership (GARDP), a non-profit product development partnership, hosted by the Drugs for Neglected Diseases Initiative (DNDi) and founded in association with the World Health Organization (WHO). It is a research and development initiative addressing global public health needs by developing, delivering and assuring sustainable access to new or improved antibiotic treatments. GAMRIF funding will support GARDP to develop and deliver new treatments for drug-resistant infections across the following three programmes: (1) Serious bacterial infections (SBIs); (2) Children’s antibiotics (neonatal sepsis and paediatric development); and (3) Sexually transmitted infections (STIs).
UK Public Health Rapid Support Team (UK-PHRST) - Rapid Deployment and Capacity Strengthening
UK - Department of Health and Social Care (DHSC)
This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC). The UK Public Health Rapid Support Team (UK-PHRST) is the primary mechanism for the UK Government to deploy technical expertise in outbreak response to ODA-eligible countries, stopping a public health threat from becoming a broader health emergency. It is a partnership between the UK Health Security Agency (UKHSA, formerly Public Health England (PHE)) and the London School of Hygiene and Tropical Medicine (LSHTM) and was established in 2016 in response to lessons learned from the West Africa Ebola outbreak. The UK-PHRST comprises public health experts who work to address the threat posed by infectious disease outbreaks in low- and middle- income countries (LMICs) through an integrated triple remit of: (1) Outbreak Response: Rapidly investigate and respond to disease outbreaks at source in LMICs to stop a public health threat from becoming a broader health emergency by deploying specialist public health experts; (2) Research: Deliver rigorous, collaborative research with partners to improve the evidence base for best practice in epidemic preparedness and response; and (3) Capacity Strengthening: Strengthen leadership, systems and technical capacity for an improved response to disease outbreaks in ODA-eligible countries. This project was not put out to an open, competitive tender process because UKHSA is an executive agency of DHSC with a mandate to deliver on pandemic preparedness and therefore exempt from the tender process as it is within DHSC’s body of expertise.
UK Vaccine Network (UKVN)
UK - Department of Health and Social Care (DHSC)
The UK Vaccine Network (UKVN) is an Official Development Assistance (ODA) funded UKaid programme from the UK Department of Health and Social Care (DHSC). It supports the development of vaccines and vaccine technology for infectious diseases with the potential to cause an epidemic in low- and middle-income countries (LMICs), focusing on areas of market failure. UKVN has identified a range of human diseases with epidemic potential in LMICs for which the development of vaccines is a priority. The long-term aims of this programme are to prevent outbreaks of diseases with epidemic potential through proactive vaccination campaigns or to control them through quick development of new vaccines and/or responsive vaccination campaigns upon outbreak detection. UKVN focuses on human and zoonotic diseases with epidemic potential in humans, from 12 priority pathogen families, alongside Disease X (a pandemic pathogen that has not yet been characterised).
UK Vaccine Network (UKVN) - BactiVac Network - Bacterial Vaccinology Competition
UK - Department of Health and Social Care (DHSC)
This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s UK Vaccine Network (UKVN) which supports the development of vaccines and vaccine technology for infectious diseases with the potential to cause an epidemic in low- and middle-income countries (LMICs), focusing on areas of market failure. UKVN has identified a range of human diseases with epidemic potential in LMICs for which the development of vaccines is a priority. The BactiVac Network aims to accelerate the development of vaccines against bacterial infections to reduce antimicrobial use in humans and animals, specifically in LMICs. UKVN funding to BactiVac supports projects that develop vaccines to prevent and/or minimise the emergence and transmission of antimicrobial resistance. A partnership between at least two organisations is a funding requirement, with at least one partner based in the UK, and prioritising partnerships with LMIC researchers. The primary aim of the funding is to encourage the establishment of new, diverse research projects and partnerships which can progress to gain preliminary data and establish their reputation, enabling them to obtain further investment. Funding will also support other UKVN activities which promote collaboration across the membership, particularly for members based in LMICs.
UK Vaccine Network (UKVN) - Coalition for Epidemic Preparedness Innovations (CEPI) - Development of Vaccines Against Diseases with Epidemic Potential
UK - Department of Health and Social Care (DHSC)
This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s UK Vaccine Network (UKVN) which supports the development of vaccines and vaccine technology for infectious diseases with the potential to cause an epidemic in low- and middle-income countries (LMICs), focusing on areas of market failure. UKVN has identified a range of human diseases with epidemic potential in LMICs for which the development of vaccines is a priority. CEPI (the Coalition for Epidemic Preparedness Innovations) is a global public-private partnership established following the 2014-16 West African Ebola epidemic to accelerate development of, and equitable access to, vaccines against emerging infectious diseases of epidemic and pandemic potential. It pools funding from sovereign donors and major philanthropic organisations to: (1) Support the advancement of vaccine candidates for known priority pathogens in LMICs; (2) Advance vaccine platform technology to support accelerated responses to an unknown pathogen (Disease X); and (3) Address key barriers to vaccine access in LMICs, such as distribution of manufacturing capacity.
UK Vaccine Network (UKVN) - Engineering and Physical Sciences Research Council (EPSRC) - Future Vaccine Manufacturing Research Hubs Competition 2 (2023-2028)
UK - Department of Health and Social Care (DHSC)
This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s UK Vaccine Network (UKVN) which supports the development of vaccines and vaccine technology for infectious diseases with the potential to cause an epidemic in low- and middle-income countries (LMICs), focusing on areas of market failure. UKVN has identified a range of human diseases with epidemic potential in LMICs for which the development of vaccines is a priority. UKVN is collaborating with the Engineering and Physical Sciences Research Council (EPSRC) to run Stage 2 of the Vaccine Manufacturing Research Hubs competition, which funds four hubs (including the two funded in Stage 1). The first stage of the Future Vaccine Manufacturing Research Hubs competition prioritised the development of vaccine products through research into improved vaccine manufacturing. The second stage continues to fund work of the same nature. As in the first competition, the hubs seek to: (1) Develop tools and technologies that allow for easier and quicker manufacturing of vaccines in emergencies; (2) Redesign existing vaccines to make them cheaper and easier to manufacture and easier to deliver in LMIC settings; and (3) Provide bespoke support for researchers developing vaccines for diseases which primarily affect LMICs, so that the vaccines they are developing are as rapid and cost-effective to manufacture as possible. The projects are expected to collaborate with LMIC researchers and industry to support their work. This project was not put out to an open, competitive tender process because, as a non-departmental public body of the UK government, EPSRC is uniquely positioned to manage research calls.
UK Vaccine Network (UKVN) - Medicines and Healthcare products Regulatory Agency (MHRA) - Global Health Security
UK - Department of Health and Social Care (DHSC)
This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s UK Vaccine Network (UKVN) which supports the development of vaccines and vaccine technology for infectious diseases with the potential to cause an epidemic in low- and middle-income countries (LMICs), focusing on areas of market failure. UKVN has identified a range of human diseases with epidemic potential in LMICs for which the development of vaccines is a priority. This project is a collaboration between UKVN, DHSC’s Global AMR Innovation Fund (GAMRIF) and the Medicines and Healthcare products Regulatory Agency (MHRA). The UKVN Work Package supports epidemic and pandemic preparedness by expanding the portfolio of research reagents for emerging viruses. Reagents are chemical compounds that trigger chemical reactions and are therefore vital to laboratory research and vaccine development. Simple and timely access to high quality research reagents would accelerate the development of vaccines against emerging infectious diseases, particularly for scientists from LMICs, which are frequently the worst affected. The existing Centre for AIDS Reagents (CFAR) repository at the MHRA has successfully provided a sustained research reagent resource to the scientific community since 1989. Using their existing network and successful operating model, UKVN funding allows CFAR to expand its scope to become the Centre for Infectious Disease Reagents (CIDR) and encourage leading laboratories to deposit state of the art research materials to their repository and produce and commission new reagents. These materials will be prioritised to organisations in LMICs which will benefit from free of charge access. For more information on the GAMRIF work package please see GB-GOV-10-GAMRIF-WP12-MHRA. This project was not put out to an open, competitive tender process because MHRA is an executive agency of DHSC and therefore exempt from the tender process as it is within DHSC’s body of expertise.
Global Antimicrobial Resistance Innovation Fund (GAMRIF)
UK - Department of Health and Social Care (DHSC)
The Global Antimicrobial Resistance Innovation Fund (GAMRIF) is an Official Development Assistance (ODA) funded UKaid programme from the Department of Health and Social Care (DHSC). It supports high-quality research and development (R&D) around the world to reduce the threat of antimicrobial resistance (AMR) in humans, animals, and the environment for the benefit of people in low- and middle-income countries (LMICs), focussing on product development (such as therapeutics, alternatives, vaccines, diagnostics and beyond). GAMRIF delivers through bilateral partnerships, global initiatives, and product development partnerships (PDPs) to establish international research partnerships with industry, academia, and governments. This approach enables it to collaborate with, and leverage additional funding from, other global donors to develop innovative One Health* solutions to tackle AMR in LMICs and increase the availability of context-specific, accessible, and affordable innovations for LMICs. (*One Health is an integrated, unifying approach that aims to sustainably balance and optimise the health of people, animals and ecosystems. It recognises that the health of humans, domestic and wild animals, plants, and the wider environment (including ecosystems) are closely linked and interdependent.)
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Nurturing breakthrough technologies to solve the global grand challenges of Antimicrobial Resistance (AMR) in the Environment
UK - Department of Health and Social Care (DHSC)
This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) which funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. This project is delivered in partnership with the Centre for Cellular and Molecular Platforms (C-CAMP) to nurture promising technologies that can solve the global challenges of AMR in the environment. A national and international call for applications (‘AMR Challenge’) will identify innovative solutions addressing prioritised AMR challenges in the environment for the benefit of LMICs. The Challenge will be specific for AMR in the environment with impact across the One Health* domains of human, animal and the environment. The India AMR Innovation Hub’s large stakeholder network may be leveraged to advance Challenge-funded innovations. (*One Health is an integrated, unifying approach that aims to sustainably balance and optimise the health of people, animals and ecosystems. It recognises that the health of humans, domestic and wild animals, plants, and the wider environment (including ecosystems) are closely linked and interdependent.)
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - FAILSAFE (Fungal AMR Innovations for low- and middle-income countries): Solutions and Access for Everyone
UK - Department of Health and Social Care (DHSC)
This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) which funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. Delivered in partnership with the University of Exeter, this is a pioneering initiative which aims to address the urgent and underfunded challenge of fungal antimicrobial resistance (fAMR). It will foster global research and development to create impactful products and solutions for fAMR across the One Health* spectrum by providing funding for small to large scale research projects in basic and clinical medical mycology, focusing on LMICs, where the effects of fAMR are particularly severe. (*One Health is an integrated, unifying approach that aims to sustainably balance and optimise the health of people, animals and ecosystems. It recognises that the health of humans, domestic and wild animals, plants, and the wider environment (including ecosystems) are closely linked and interdependent.)
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Global Health Security and Medicines and Healthcare products Regulatory Agency (MHRA)
UK - Department of Health and Social Care (DHSC)
This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) which funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. This partnership with the Medicines and Healthcare products Regulatory Agency (MHRA) aims to provide regulatory and policy support to GAMRIF funded activities globally by: (1) Providing early-stage regulatory advice through existing innovation accelerator; (2) Underpinning regulatory scientific research to establish the scientific framework for assuring the quality of products; and (3) Providing assistance on the preparation of calibrants and running controls required to measure medicinal products’ critical quality attributes. MHRA will develop non-mandatory regulatory guidance that draws on national guidelines and advice from national regulators, maximising the likelihood that innovative products developed within GAMRIF funded portfolios secure regulatory approval in both LMICs and high-income countries (HICs). This project was not put out to an open, competitive tender process because MHRA is an executive agency of DHSC and therefore exempt from the tender process as it is within DHSC’s body of expertise.
UK Vaccine Network (UKVN) - UK Health Security Agency (UKHSA) - Vaccine Technology Development
UK - Department of Health and Social Care (DHSC)
This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s UK Vaccine Network (UKVN) which supports the development of vaccines and vaccine technology for infectious diseases with the potential to cause an epidemic in low- and middle-income countries (LMICs), focusing on areas of market failure. UKVN has identified a range of human diseases with epidemic potential in LMICs for which the development of vaccines is a priority. UKVN funded the UK Health Security Agency (UKHSA) to deliver a programme of seven projects that will advance vaccine development for diseases of epidemic potential for the benefit of people in LMICs. The projects cover a range of pathogens, which have been identified as being a priority area of investment due to lack of current vaccine availability and likelihood of epidemic threat. The projects are primarily focused on enabling activities, such as preclinical model or assay development, to support the development of vaccine candidates for priority pathogens, including through increasing the range of settings where vaccine development and evaluation can take place without a need for higher-containment facilities, which will support future work in LMICs. This project was not put out to an open, competitive tender process because UKHSA is an executive agency of DHSC with a mandate to deliver on pandemic preparedness and therefore exempt from the tender process as it is within DHSC’s body of expertise.
UK Vaccine Network (UKVN) - Innovate UK - Vaccine Development for Diseases with Epidemic Potential Competition
UK - Department of Health and Social Care (DHSC)
This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s UK Vaccine Network (UKVN) which supports the development of vaccines and vaccine technology for infectious diseases with the potential to cause an epidemic in low- and middle-income countries (LMICs), focusing on areas of market failure. UKVN has identified a range of human diseases with epidemic potential in LMICs for which the development of vaccines is a priority. UKVN is funding Innovate UK to run the Vaccine Development for Diseases with Epidemic Potential competition. The competition aims to support projects seeking to develop vaccines, vaccine platform technologies and manufacturing technologies that will enable an effective, rapid response during future outbreaks of diseases of epidemic potential in LMICs. The projects include work that has progressed from earlier UKVN-Innovate UK competitions, including the Vaccines for Epidemic Diseases: Readiness for Clinical Development and Regulatory Submission Competition, Innovate Vaccine Development Competition 2017-2020, Innovate Preclinical Vaccine Development Competition 2017-2021, and Innovate Clinical Vaccine Development Competition 2018-2021. The successive funding allows for successful previous projects to receive follow on funding and progress vaccine candidates down the developmental pipeline. This project was not put out to an open, competitive tender process because, as a non-departmental public body of the UK government, Innovate UK is uniquely positioned to manage research calls.
'Highlight' Health financing for universal health coverage in the era of shocks, monitoring risks and opportunities in Sub-Saharan Africa
DEPARTMENT FOR SCIENCE, INNOVATION AND TECHNOLOGY
"The proposed research draws on the World Health Organization framework for monitoring progress towards UHC. The framework identifies three areas for monitoring: financing arrangements; intermediate outcomes of efficiency and equity; and UHC goals of service coverage and affordable health expenditures. Our research applies this framework to assess health financing at the national and subnational levels in five Sub-Saharan African countries with varied degrees of fiscal decentralisation and income levels: Tanzania, Malawi, Zambia, Senegal and Sierra Leone. Our research describes the evolution of health financing arrangements before and after COVID-19, and progress in relation to efficiency and equity of health financing and UHC goals. This research draws on routine household surveys, government and donor expenditure information systems, and global data from the World Health Organzaition and the Organisation for Economic Cooperation and Development" COVID-19
Support to Polio Eradication through GPEI - 2020-2025
UK - Foreign, Commonwealth Development Office (FCDO)
To achieve the global goal of polio eradication while improving health systems we will provide funding to GPEI.
Advanced filters
To search for Programmes in a specific time period, please enter the start and end dates.